Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
Hodgkin's Lymphoma
DRUG: TGR-1202 + brentuximab vedotin
Maximum Tolerated Dose acceptable for participants, To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities, 21 days (1 cycle of therapy)
Overall Response Rate, To assess the overall response rate (ORR) of TGR-1202 in combination with brentuximab vedotin in patients with Hodgkin's lymphoma, Up to 1 year
Duration of Response, To evaluate the duration of response of TGR-1202 in combination with brentuximab vedotin, Up to 1 year
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.